Next Article in Journal
Neonatal Consumption of Oligosaccharides Greatly Increases L-Cell Density without Significant Consequence for Adult Eating Behavior
Next Article in Special Issue
Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review
Previous Article in Journal
Effect of Anthocyanin-Rich Tart Cherry Extract on Inflammatory Mediators and Adipokines Involved in Type 2 Diabetes in a High Fat Diet Induced Obesity Mouse Model
Previous Article in Special Issue
Influence of Growth Hormone and Glutamine on Intestinal Stem Cells: A Narrative Review
Open AccessArticle

Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome

Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
Pharmacology, Toxicology and Clinical Pharmacology Department, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania
Department of Gastroenterology, Octavian Fodor Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania
Diasan Medical Center, 400516 Cluj-Napoca, Romania
Author to whom correspondence should be addressed.
Nutrients 2019, 11(9), 1968;
Received: 30 July 2019 / Revised: 12 August 2019 / Accepted: 16 August 2019 / Published: 21 August 2019
(This article belongs to the Special Issue Nutritional Management of Gastrointestinal Diseases and Disorders)
Dysbiosis is a condition that can cause various clinical disorders, from gastrointestinal problems to allergies or even cancer. Resetting the microbiota using antibiotics and/or probiotics could be a possible therapy for many diseases. The aim of this study was to evaluate the effects of three treatment regimens in patients with irritable bowel syndrome (IBS). The regimens were short-term rifaximin treatment (10 days) followed by either a nutraceutical agent (G1) or a low- Fermentable, Oligo-, Di-, Monosaccharide and Polyol (FODMAP) diet (24 days) (G3) or treatment with MegaSporeBiotic a mixture of spores of five Bacillus spp. for medium-term (34 days) (G2). Ninety patients with IBS without constipation were enrolled and divided into three groups (G1, G2, G3). Patients in G1 and G3 were evaluated over four visits (baseline/first day (V1), 10 days (V2), 34 days (V3), 60 days (V4)), and, those in G2 over three visits (V1, V3, V4). Severity score, quality of life, and parameters from the rectal volume sensation test were determined. The results demonstrated that patients treated with MegaSporeBiotic, compared with those treated with rifaximin followed by nutraceutical or low-FODMAP diet, had similar severity scores and rectal volume sensation test results for all parameters tested and statistically significant improvement in measurements of quality of life. View Full-Text
Keywords: irritable bowel syndrome; FODMAP; Bacillus spores; probiotics; rifaximin irritable bowel syndrome; FODMAP; Bacillus spores; probiotics; rifaximin
Show Figures

Figure 1

MDPI and ACS Style

Catinean, A.; Neag, A.M.; Nita, A.; Buzea, M.; Buzoianu, A.D. Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome. Nutrients 2019, 11, 1968.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop